Huntington's Disease Market Size Expected to Surge with a Significant CAGR of 22.5% in the 7MM During the Study Period [2018-30] | DelveInsight

The untapped market of Huntington's Disease is anticipated to expand primarily because of the introduction of novel emerging therapies, rising prevalence and elderly population, increased R&D activities and the advent of genetic testing. There is currently no approved therapy to cure this disease, however, some future treatments are addressing crucial areas of unmet medical need, such as a lack of disease-modifying therapy choices. 

LAS VEGAS, Oct. 8, 2021 /PRNewswire/ -- DelveInsight's Huntington's Disease Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Huntington's Disease market share of the individual therapies, current and forecasted Huntington's Disease market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). 

Several essential outcomes extracted from the Huntington's Disease Market Report: 

• As per the DelveInsight analysis, overall  Huntington's Disease prevalent cases are expected to grow during the forecast period, due to population aging, varied phenotypic penetrance, and increased life expectancy.
• The largest Huntington's Disease market share in the 7MM was observed in the United States increasing at a CAGR of 20.3% during the study period.
• In April 2017, the United States Food and Drug Administration (USFDA) approved Austedo (deutetrabenazine) by Teva Pharmaceuticals for treating chorea associated with Huntington's Disease. Another USFDA approved therapy is Xenazine (tetrabenazine). These therapies only work in one Huntington's Disease symptomatic area, i.e., treatment of chorea. Currently, there is no curative Huntington's Disease treatment present in the market.
• Wave Life Sciences (WVE-120102 and WVE-120101) and Roche/Ionis (tominersen) both reported disappointing results in Huntington's disease clinical trials. Roche's product has been discontinued, leaving a void in late-stage Huntington's disease trials. After the failure of tominersen, WVE-120102, and WVE-120101, the Huntington's disease community is eyeing Uniqure's gene therapy, i.e., AMT-130.
• Key pharma players working proactively in Huntington's Disease therapeutic market are Prilenia Therapeutics, Neurocrine Biosciences, Annexon Biosciences, SOM Biotech, Vaccinex, UniQure Biopharma, Wave life sciences/Takeda, Mitochon Pharmaceuticals, PTC Therapeutics, Novartis, AOP Orphan Pharmaceuticals and others have the potential to create a significant positive shift in the market size. 
• The launch of emerging therapies in the Huntington's Disease domain like Ingrezza (valbenazine), Pridopidine, SOM3355 (bevantolol), SRX246, Pepinemab (VX15/2503), AMT-130, ANX005 will significantly impact the Huntington's Disease market during the forecast period.

Discover more about therapies set to grab substantial Huntington's Disease market share @ Huntington's Disease Market Landscape 

Huntington's Disease: Overview 

Huntington's Disease is a genetic neurodegenerative disorder caused by a CAG triplet repeat expansion in the gene encoding huntingtin. A fatal hereditary disease that causes the progressive breakdown of nerve cells in the brain which usually deteriorates a person's physical and mental abilities during their prime working years and has no cure.

Huntington's Disease Epidemiology Segmentation

DelveInsight analyses that the overall prevalent cases of Huntington's Disease were estimated to be around 80,170 in the 7MM in 2020, which are expected to grow during the forecast period (2021–2030).

The most prominent Huntington's Disease prevalent cases throughout the 7MM, are found in the United States with the total number of Huntington's Disease prevalent cases found to be 42,414 in 2020.

The Huntington's Disease Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Huntington's Disease Prevalent Cases
• Symptom-specific Prevalent Huntington's Disease Cases
• Age-specific Prevalent Huntington's Disease Cases
• Diagnosed and Treatable Huntington's Disease Cases 

Download report to understand which demographic factors are guiding Huntington's Disease epidemiology trends @ Huntington's Disease Epidemiological Insights 

Huntington's Disease Market

Austedo and Xenazine are the only USFDA approved symptomatic therapies, but their approved indication is the treatment of chorea associated with Huntington's disease. The Huntington's Disease market currently has no therapy options to cure Huntington's Disease. There are no therapies that can change the course of Huntington's disease. Medication, on the other hand, can only relieve certain symptoms of movement and psychiatric disorders. The treatment strategies include the usage of medications such as Antidepressants, Antipsychotics, Anxiolytics, Antiepileptics, and others to address particular symptoms such as depression, mood swings, involuntary/abnormal movements, anxiety, and other psychiatric symptoms.

Due to the unavailability of curative therapies in the rare Huntington's Disease domain, opportunities to discover and experiment more in this life-threatening disease are present. Many pharmaceutical companies are entering the  Huntington's Disease market space in order to explore new and emerging therapies like Teva Pharmaceutical, Prilenia Therapeutics, Neurocrine Biosciences, Annexon Biosciences, SOM Biotech, Azevan Pharmaceuticals, Vaccinex, UniQure Biopharma, Wave life sciences/Takeda, Medesis Pharma, and others.

For the forecast period, the pipeline candidates are expected to drive the rise in Huntington's Disease market size. Some of these treatments are addressing important areas of unmet medical need, i.e., lack of disease-modifying options for the treatment. Few therapies that are under investigation include Valbenazine, also known as Ingrezza, developed by Neurocrine Biosciences, an investigational treatment for chorea associated with Huntington's Disease. It is a selective VMAT2 inhibitor and operates by reducing the amount of dopamine released in a region of the brain that controls movement and motor function. Vaccinex is being developed by Pepinemab for Huntington's Disease and has recently completed the SIGNAL trial (NCT02481674), a late-stage clinical study of Pepinemab for Huntington's Disease. 

ANX005 by Annexon is another clinical-stage investigational monoclonal antibody intended to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. 

Unfortunately, companies such as Wave Life Sciences (WVE-120102 and WVE-120101) and Roche/Ionis (tominersen) reported disappointing results in Huntington's Disease clinical trials. Roche's product has been discontinued, as interim data from the Phase III GENERATION HD1 clinical trial indicated that the therapy was not benefiting the participants anymore. The void left due to these failures is an opportunity for key pharma players to be aware of Huntington's Disease market growth potential.

Learn more about the current and emerging treatments @ Huntington's Disease Market Analysis

Huntington's Disease Market: Drivers and Barriers

The increase in Huntington's Disease prevalence is considered to be the major driving force for Huntington's Disease market size growth in the coming years.  Huntington's Disease market has also witnessed an increase in therapeutic assets development and the expected launch of these upcoming therapies shall assist in boosting the market.

Huntington's Disease is exceptionally rare, so there is a requirement for more data and knowledge of this rare but threatening disease. An incomplete understanding of the disease acts as an obstruction for developing new therapies. A high number of undiagnosed and unreported cases also contribute to the lack of awareness of this condition. There is a strong need for regional Huntington's Disease registration centers offering consented and consistent therapy recommendations. 

Nonetheless, even with the limited access to information on Huntington's Disease, Pharma players are devotedly working to develop low-cost and less time-consuming medications with better adherence in patients. With an immense scope of new therapeutic developments in the Huntington's Disease market, the launch of emerging therapies is expected to change the Huntington's Disease market paradigm and contribute to an upward rise in the coming years.

Scope of the Huntington's Disease Market Report

• Study Period: 2018-30
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Companies: Teva Pharmaceutical, Prestwick Pharmaceutical/Lundbeck, Neurocrine Biosciences, Prilenia Therapeutics, Som Biotech, Azevan Pharmaceuticals, Vaccinex, Uniqure, Annexon Bioscience, Wave life sciences/Takeda and others
• Key Huntington's Disease Pipeline Therapies: Ingrezza (Valbenazine), Pridopidine, ANX005, Bevantolol (SOM3355), SRX246, Pepinemab, AMT-130, WVE-003, NanoLithium (NP03), and others
• Therapeutic Assessment: Huntington's Disease current marketed and emerging therapies
• Market Dynamics: Huntington's Disease market drivers and barriers 
• Key Cross Competition
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• Case Studies
• KOL's Views
• Analyst's Views
• Market Access and Reimbursement Scenario

Get in touch with our Business executive @ Huntington's Disease Market Landscape Analysis 

Table of Contents 

Learn more about the report offerings @ Huntington's Disease Market Outlook

Related Reports

Huntington's Disease Pipeline

DelveInsight's, "Huntington's Disease - Pipeline Insight, 2021," report offers rich insights into epidemiology, treatments, pipeline therapies, and key companies including Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and several others. 

Huntington's Disease - Epidemiology

DelveInsight's 'Huntington's Disease - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Huntington's Disease epidemiology in the 7MM.

Multiple Myeloma Market

DelveInsight's 'Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030' report offers rich insights into current and emerging treatments, pipeline therapies, and key pharmaceuticals including GlaxoSmithKline, Bristol-Myers Squibb/Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical (Millennium Pharmaceuticals), Sanofi, Karyopharm Therapeutics, Janssen Biotech, AbbVie, Celgene, RAPA Therapeutics, Pfizer (Array Biopharma), Cellectar Biosciences, BioLineRx, ExCellThera, Precision BioSciences, and many others. 

Neurofibromatosis Type-2 (NF2) Market

DelveInsight's 'Neurofibromatosis Type-2 (NF2)– Market Insights, Epidemiology, and Market Forecast—2030' report deliver an in-depth understanding of current treatment practices, emerging drugs, market share of the individual therapies and key pharmaceuticals including AstraZeneca, Novartis, Genentech, Takeda, Recursion Pharmaceuticals, Pfizer, and few others.

Narcolepsy Market

DelveInsight's 'Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030' report provides deep insights into the Narcolepsy market, epidemiology, pipeline therapies, and key companies including Cephalon Inc., Jazz Pharmaceuticals, and several others.

Multiple Organ Dysfunction Syndrome Market

DelveInsight's "Multiple Organ Dysfunction Syndrome Market Insights, Epidemiology, and Market Forecast-2030" report proffers thorough details into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Dart Neuroscience, Corcept Therapeutics, Cerecin, and various others. 

Persistent Epithelial Defect Market

DelveInsight's "Persistent Corneal Epithelial Defects (PEDs) - Market Insights, Epidemiology, and Market Forecast - 2030" report provides a detailed overview of the disease. Key companies include Dompe Farmaceutici, OcuNexus Therapeutics, Eyevance Pharmaceuticals, Noveome Biotherapeutics, RegeneRx Biopharmaceuticals, Recordati Rare Diseases, Mimetech, and others are developing Persistent Epithelial Defect therapies. 

Chronic Progressive Multiple Sclerosis Market

DelveInsight's "Chronic Progressive Multiple Sclerosis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the disease, market, epidemiology, pipeline therapies, and key companies.

Adrenocortical Carcinoma  Market 

DelveInsight's "Adrenocortical Carcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adrenocortical Carcinoma, historical and forecasted epidemiology as well as market, epidemiology, pipeline therapies, and key companies involved.

Alagille Syndrome Market 

DelveInsight's 'Alagille Syndrome (ALGS) – Market Insights, Epidemiology, and Market Forecast—2030' report proffer detailed analysis of epidemiology, treatments, pipeline therapies, and key companies including Mirum Pharmaceuticals, Albireo, and many others.

Browse Through Our Blog Posts

Is the cure for Huntington's disease on the horizon?

• Progressive neurological disorders such as Parkinson disease (PD), motor neuron disease (MND), Huntington disease (HD), or multiple sclerosis (MS), despite the advent of technological advances in healthcare and medical sciences, poses a huge burden worldwide, which is set to increase in coming decades.

Origins of the depressive behavior in Huntington's disease

• Huntington's disease is an incurable genetic disorder that causes the progressive breakdown of nerve cells in the brain.

Angelman Syndrome Market: Insights Into The Recent Late-Stage Drug Failures And Novel Approaches To Treating This Rare Neurogenetic Disorder

• Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. The first sign of a child suffering from Angelman syndrome is a delay in development, such as the inability to sit without support or making incoherent babbling sounds.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg